Charles McDermott Net Worth

Charles McDermott biography

Charles Douglas McDermott serves as Independent Director of the Company. r. McDermott has served as Chairman, President and Chief Executive Officer of Primmune Therapeutics, Inc., a privately-held biotechnology company, since March 2019. From September 2017 to May 2018, Mr. McDermott served as President and Chief Business Officer of Impact Biomedicines, Inc., a privately-held biotechnology company. Prior to that, Mr. McDermott served as President and Chief Business Officer of Kala Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from June 2015 to August 2017. Previously, he served as Interim President and Chief Business Officer of Kala from October 2014 to June 2015 and as Executive Vice President of Business Development of Kala from June 2013 to October 2014. Prior to joining Kala, Mr. McDermott served first as Director and then Vice President of Business Development, Eye Care and Drug Delivery at Allergan plc, a publicly-held global pharmaceutical company, where he worked from April 2005 to May 2013. Prior to joining Allergan, Mr. McDermott held a variety of business development positions at deCODE Genetics, Inc. (now DGI Resolutions, Inc.), a privately-held biopharmaceutical company, from January 2001 to March 2005. Prior to deCODE Genetics, Mr. McDermott was a research scientist in the angiogenesis pharmacology group at Agouron Pharmaceuticals, Inc. Mr. McDermott currently serves as an Advisor to Omega Funds, an investment firm that creates and invests in life sciences companies. Mr. McDermott holds an M.B.A. from the University of San Diego, an M.A. in Molecular, Cellular and Developmental Biology from the University of California at Santa Barbara, a B.S. in Biochemistry and Molecular Biology from the University of California Santa Cruz and a Certificate in Clinical Trial Design and Management from the University of California San Diego Extension.

How old is Charles McDermott?

Charles McDermott is 48, he's been the Independent Director of Equillium Inc since 2018. There are 13 older and 3 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.

What's Charles McDermott's mailing address?

Charles's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 105, , LA JOLLA, CA, 92037.

Insiders trading at Equillium Inc

Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski y Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.

What does Equillium Inc do?

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

Equillium Inc executives and stock owners

Equillium Inc executives and other stock owners filed with the SEC include:

• Krishna Polu,
  Executive Vice President - Research and Development, Chief Medical Officer
• Bruce Steel,
  President, Chief Executive Officer, Director
• Daniel Bradbury,
  Executive Chairman of the Board
• Dr. Krishna R. Polu,
  Consultant
• Dr. Stephen Connelly Ph.D.,
  Chief Scientific Officer & Director
• Bruce D. Steel C.F.A.,
  Co-Founder, Pres, CEO & Director
• Stephen Connelly,
  Chief Scientific Officer, Director
• Daniel Mark Bradbury,
  Exec. Chairman
• Mark Pruzanski,
  Independent Director
• Charles McDermott,
  Independent Director
• Bala Manian,
  Independent Director
• Martha Demski,
  Independent Director
• Matthew Ritter,
  Vice President - Corporate Development
• Maple Fung,
  Vice President - Clinical Development
• Christine Zedelmayer,
  Chief Operating Officer, Senior Vice President
• Jason Keyes,
  Chief Financial Officer
• Jason A. Keyes,
  Chief Financial Officer
• Dr. Dolca Thomas M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Joel M. Rothman,
  Chief Devel. Officer
• Michael Moore,
  VP of Investor Relations & Corp. Communications
• Christine Zedelmayer M.B.A., P.M.P.,
  Sr. VP & COO
• Yu (Katherine) Xu,
  
• Sa Biocon,
  10% owner
• Dolca Thomas,
  Chief Medical Officer
• Joel Rothman,
  Chief Development Officer
• Barbara Troupin,